In vitro metabolism studies of erythraline, the major spiroalkaloid from Erythrina verna

BMC Complementary and Alternative Medicine

João Luis Callegari Lopes²  Letícia Veras Costa-Lotufo⁴  Norberto Peporine Lopes²  Hans-Ulrich Humpf³  Lucas Rossi Sartori³  Aline Cavalli Bizaro¹  Denise Brentan Silva¹  Thais Guaratini¹ 

[1] Lychnoflora Pesquisa e Desenvolvimento em Produtos Naturais LTDA, Rua Ângelo Mestriner 263, Ribeirão Preto, SP, Brazil, Ribeirão Preto, SP, Brazil;Núcleo de Pesquisa em Produtos Naturais e Sintéticos (NPPNS), Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP), Universidade de São Paulo (USP), Av. Café s/nº, 14040-903 Ribeirão Preto, SP, Brazil;Institute of Food Chemistry, Westfälische Wilhelms-Universität Münster, Corrensstrasse 45, 48149 Münster, Germany;Departamento de Fisiologia e Farmacologia, Faculdade de Medicina, Universidade Federal do Ceará, 60430-270 Fortaleza, CE, Brazil

关键词: Erythrina alkaloids;    Jacobsen catalyst;    Fabaceae;    Erythrina verna;    in vitro metabolism;    Erythraline;    Spirocyclic alkaloids;   

Others  :  1220260
DOI  :  10.1186/1472-6882-14-61

 received in 2013-10-02, accepted in 2014-02-12,  发布年份 2014

【 摘 要 】

Background

Erythrina verna, popularly known as “mulungu”, is a Brazilian medicinal plant used to treat anxiety. Erythrina alkaloids have been described in several species of Erythrina, which have biological and therapeutic properties well known that include anxiolytic and sedative effects.

Methods

In this work, in vitro metabolism of erythraline (1), the major spirocyclic alkaloid of Erythrina verna, was studied in the pig cecum model and by biomimetic phase I reactions. The biomimetic reactions were performed with Jacobsen catalyst to produce oxidative metabolites and one metabolite was isolated and evaluated against cancer cells, as HL-60 (promyelocytic leukemia), SF-295 (Glioblastoma) and OVCAR-8 (ovarian carcinoma).

Results

Erythraline exhibited no metabolization by the pig microbiota and a main putative metabolite was formed in a biomimetic model using Jacobsen catalyst. This metabolite was isolated and identified as 8-oxo-erythraline (2). Finally, erythraline and the putative metabolite were tested in MTT model and both compounds showed no important cytotoxic activity against tumor cells.

Conclusions

The alkaloid erythraline was not metabolized by intestinal microbiota, but it was possible to identify its oxidative metabolite from biomimetic reactions. So these data are interesting and stimulate other studies involving this alkaloid, since it is present in phytomedicine products and there are not reported data about the metabolism of erythrina alkaloids.

【 授权许可】

   
2014 Guaratini et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]San Miguel-Chavez R, Soto-Hernandez M, Ramos-Valdivia AC, Kite G: Alkaloid production in elicited cell suspension cultures of Erythrina americana Miller. Phytochem Rev 2007, 6:167-173.
• [2]Carvalho PER: Mulungu (Erythrin velutina). Colombo: Circular Técnica 160: Embrapa Florestas; 2008.
• [3]Amer ME, Shamma M, Freyer AJ: The tetracyclic Erythrina alkaloids. J Nat Prod 1991, 54:329-363.
• [4]Wanjala CCW, Majinda RRT: Two novel glucodienoid alkaloids from Erythrina latissima seeds. J Nat Prod 2000, 63:871-873.
• [5]Wanjala CCW, Juma BF, Bojase G, Gache BA, Majinda RRT: Erythrinaline alkaloids and antimicrobial flavonoids from Erythrina latissima. Planta Med 2002, 68:640-642.
• [6]Juma BF, Majinda RRT: Erythrinaline alkaloids from the flowers and pods of Erythrina lysistemon and their DPPH radical scavenging properties. Phytochemistry 2004, 65:1397-1404.
• [7]Tanaka H, Etoh H, Shimizu H, Oh-Ochi T, Terada Y, Tateishi Y: Erythrinan alkaloids and isoflavonoids from Erythrina poeppigiana. Planta Med 2001, 67:871-873.
• [8]Rodrigues VEG, Carvalho DA: Plantas Medicinais do Cerrado. Lavras: UFLA; 2001.
• [9]Flausino O Jr, Santos LA, Verli H, Pereira AM, Bolzani VS, Nunes-De-Souza RL: Anxiolytic effects of erythrinian alkaloids from Erythrina mulungu. J Nat Prod 2007, 70:48-53.
• [10]Flausino O Jr, Pereira AM, Bolzani VS, Nunes-De-Souza RL: Effects of erythrinian alkaloids isolated from Erythrina mulungu (Papilionaceae) in mice submitted to animal models of anxiety. Biol Pharm Bull 2007, 30:375-378.
• [11]Serrano MAR, Batista AND, Bolzani VD, Santos LD, Nogueira PJD, Nunes-De-Souza RL, Latif A, Arfan M: Anxiolytic-like effects of erythrinian alkaloids from Erythrina suberosa. Quim Nova 2011, 34:808-811.
• [12]Setti-Perdigão P, Serrano MAR, Flausino-Jr OA, Bolzani VS, Guimarães MZP, Castro NG: Erythrina mulungu alkaloids are potent inhibitors of neuronal nicotinic receptor currents in mammalian cells. Plos One 2013, 8:e82726.
• [13]Feitosa LGP, Guaratini T, Lopes JLC, Lopes NP, Bizaro AC, Silva DB: Aplicação de espectrometria de massas com ionização por elétron na análise de alcaloides do mulungu. Quim Nova 2012, 35:2177-2180.
• [14]Mohammed MM, Ibrahim NA, Awad NE, Matloub AA, Mohamed-Ali AG, Barakat EE, Mohamed AE, Colla PL: Anti-HIV-1 and cytotoxicity of the alkaloids of Erythrina abyssinica Lam. growing in Sudan. Nat Prod Res 2012, 26:1565-1575.
• [15]Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S: Host-Gut microbiota metabolic interactions. Science 2012, 336:1262-1267.
• [16]Brandon EFA, Raap CD, Meijerman I, Beijnen JH, Schellens JHM: An update on in vitro test methods in human hepatic drug biotransformation research pros and cons. Toxicol Appl Pharmacol 2012, 189:233-246.
• [17]Ekins S, Ring BJ, Grace J, McRobie-Belle DJ, Wrighton SA: Present and future in vitro approaches for drug metabolism. J Pharmacol Toxicol Methods 2000, 44:313-324.
• [18]Keppler K, Humpf H-U: Metabolism of anthocyanins and their phenolic degradation products by the intestinal microflora. Bioorgan Med Chem 2005, 13:5195-5205.
• [19]Hein EM, Rose K, Van’t Slot G, Friedrich AW, Humpf H-U: Deconjugation and degradation of flavonol glycosides by pig cecal microbiota characterized by fluorescence in situ hybridization (FISH). J Agric Food Chem 2008, 56:2281-2290.
• [20]Ferreira LDS, Callejon DR, Engemann A, Cramer B, Humpf HU, Barros VP, Assis MD, Silva DB, Albuquerque S, Okano LT, Kato MJ, Lopes NP: In vitro metabolism of grandisin, a lignan with anti-chagasic activity. Planta Med 2012, 78:1939-1941.
• [21]Mac Leod TCO, Faria AL, Barros VP, Queiroz MEC, Assis MD: Primidone oxidation catalyzed by metalloporphyrins and Jacobsen catalyst. J Mol Catal A Chem 2008, 296:54-60.
• [22]Niehues M, Barros VP, Emery FS, Dias-Baruffi M, Assis MD, Lopes NP: Biomimetic in vitro oxidation of lapachol: a tool to predict and analyse the in vivo phase I metabolism of bioactive compounds. Eur J Med Chem 2012, 54:804-812.
• [23]Messiano GB, Santos RAS, Ferreira LS, Simões RA, Jabor VAP, Kato MJ, Lopes NP, Pupo MT, De Oliveira ARM: In vitro metabolism study of the promising anticancer agent the lignan (-)-grandisin. J Pharm Biomed Anal 2013, 72:240-244.
• [24]Pigatto MC, de Lima MDA, Galdino SL, Pitta ID, Vessecchi R, Assis MD, dos Santos JS, Costa TD, Lopes NP: Metabolism evaluation of the anticancer candidate AC04 by biomimetic oxidative model and rat liver microsomes. Eur J Med Chem 2011, 46:4245-4251.
• [25]Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
• [26]Mantle PG, Laws I, Widdowson DA: 8-Oxo-erythraline, a naturally occurring principal alkaloid from Erythrina crista-galli. Phytochemistry 1984, 23:1336-1338.
• [27]Mohammed MM, Ibrahim NA, Awad NE, Matloub AA, Mohamed-Ali AG, Barakat EE, Mohamed AE, Colla PL: Anti-HIV-1 and cytotoxicity of the alkaloids of Erythrina abyssinica Lam. growing in Sudan. Erratun in Nat Prod Res 2013, 27:295.